Skip to Content

CD20 antibody is associated with worse COVID-19 outcomes for patients with MS

Dr Steve Simpson-Yap presents in this MEDtalk data from the largest international cohort of people with MS and COVID-19. The study shows that CD20 antibody treatment may be a risk factor for more severe COVID-19 disease among MS patients.

Steve Simpson-Yap

Få adgang til artiklen

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top